Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
This study is currently recruiting participants.
Verified June 2013
by Valeant Pharmaceuticals International, Inc.
Study NCT01007448 Information provided by Valeant Pharmaceuticals International, Inc.
First Received on November 3, 2009. Last Updated on June 11, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Lymphoma, T-Cell, Cutaneous
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
More general drug interventions related to this trial
Physiological Effects of Drugs
Sponsors listed in this trial
Valeant Pharmaceuticals International, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers